顶盖板胶质瘤（TPG）是一种生长缓慢且具有良性临床病程的中脑肿瘤。大多数 TPG 是低级别星形细胞瘤，但它们可以涵盖各种组织学肿瘤类型。伽玛刀放射外科 (GKRS) 正在探索作为 TPG 的一种潜在安全有效的治疗选择，尽管该领域的研究有限。本研究旨在评估 GKRS 对 TPG 患者的疗效和安全性，并对有关该主题的现有文献进行全面回顾。这项回顾性、单中心研究纳入了 48 名在 2005 年 9 月至 2022 年 6 月期间接受 GKRS 的连续 TPG 患者。根据放射学或组织标准进行 TPG 且至少随访 12 个月的患者有资格纳入。主要终点是局部控制以及不存在 GKRS 相关或肿瘤相关的死亡率和发病率。在中位随访 28.5 个月（范围 12-128）期间，放射学评估显示所有病例的肿瘤得到控制，其中16.7% 实现完全缓解，68.8% 实现部分缓解。 6.2%的病例出现假性进展，发病时间为3至8个月。临床结果显示，没有永久性的神经功能恶化，14.6% 的患者症状有所改善，其他患者的症状保持稳定。假性进展组中的一名患者经历了短暂的帕里诺综合征。一名患者在随访期间因无关原因死亡。 GKRS 后的平均生存时间为 123.7 个月。临床、放射学或放射外科变量均未显示与部分/完全缓解、临床改善或总体生存率相关。关于 TPG 管理的研究有限，本研究呈现了接受 GKRS 治疗的最大患者队列，以及并有相当长的随访时间。尽管有其局限性，这项研究证明了 GKRS 对 TPG 的有效性和低风险特征。版权所有 © 神经外科医生大会 2023。保留所有权利。

Tectal plate gliomas (TPGs) are midbrain tumors that grow slowly and have a benign clinical course. Most TPGs are low-grade astrocytomas, but they can encompass various histological tumor types. Gamma Knife radiosurgery (GKRS) is being explored as a potentially safe and effective treatment option for TPGs, although research in this area is limited. This study aims to evaluate GKRS's efficacy and safety in patients with TPG and provide a comprehensive review of existing literature on the topic.This retrospective, single-center study included 48 patients with consecutive TPG who underwent GKRS between September 2005 and June 2022. Patients diagnosed with TPGs based on radiological or tissue-based criteria and who had a minimum follow-up period of 12 months were eligible for inclusion. The primary end points were local control and the absence of GKRS-associated or tumor-associated mortality and morbidity.During a median follow-up of 28.5 months (range, 12-128), the radiological assessment showed tumor control in all cases, with 16.7% achieving a complete response and 68.8% achieving a partial response. Pseudoprogression occurred in 6.2% of cases, with onset ranging from 3 to 8 months. Clinical outcomes revealed no permanent neurological deterioration, with symptoms improving in 14.6% of patients and remaining stable in the others. One patient in the pseudoprogression group experienced transient Parinaud syndrome. One patient died during follow-up because of unrelated causes. The mean survival time after GKRS was 123.7 months. None of the clinical, radiological, or radiosurgical variables showed a correlation with partial/complete response, clinical improvement, or overall survival.There is limited research available on the management of TPGs, and this study presents the largest patient cohort treated with GKRS, along with a substantial follow-up duration. Despite its limitations, this study demonstrates the efficacy and low-risk profile of GKRS for TPGs.Copyright © Congress of Neurological Surgeons 2023. All rights reserved.